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AbstrAct
Objectives Guidelines recommend ACE inhibitors (ACEi), 
angiotensin receptor blockers (ARBs), calcium channel 
blockers (CCBs) and diuretics in all patients with diabetes 
mellitus. However, the effectiveness of these agents in 
South Asian and Chinese populations is unknown. We 
sought to determine whether ACEi, ARB, CCB and diuretics 
are associated with reduced mortality in South Asian, 
Chinese and other patients with diabetes.
Design Population-based cohort study using 
administrative health databases.
setting Province of British Columbia, Canada (2006–2013).
Participants Patients aged ≥35 years with incident 
diabetes.
Primary and secondary outcome measures Primary 
outcome was all-cause mortality for each medication class 
compared with untreated patients within each ethnicity. 
Treatment effect was assessed using inverse probability 
of treatment weighted Cox proportional hazards models. 
Medication adherence effect on mortality was also evaluated.
results 208 870 patients (13 755 South Asian, 22 871 
Chinese, 172 244 other Canadian) were included. ACEi 
reduced mortality in other patients (HR=0.88, 0.84–0.91), 
but power was insufficient to evaluate for benefit in 
Chinese and South Asian patients. ARB and diuretics 
reduced mortality in Chinese (ARB HR=0.64, 0.50–0.82; 
diuretics HR=0.77, 0.62–0.96) and other patients (ARB 
HR=0.69, 0.64–0.74; diuretics HR=0.66, 0.63–0.69) 
compared with untreated patients. No mortality benefit 
was observed among South Asians for any drug class 
or for CCB among all ethnicities. Higher medication 
adherence was associated with lower mortality for other 
patients only (HR=0.79, 0.72–0.86).
conclusions Effectiveness of cardiovascular risk 
reduction therapy on mortality varies considerably by 
ethnicity. Further study is needed to evaluate the mortality 
benefit of antihypertensive agents in South Asians. 
Inclusion of these ethnic groups in future clinical trials is 
essential to examine for differential responses.
IntrODuctIOn
Pharmacological treatment of hyperten-
sion in patients with type 2 diabetes mellitus 
(diabetes) is associated with significantly 
reduced mortality.1 International guidelines 
recommend routinely using antihypertensive 
medications to reduce cardiovascular risk in 
all patients with diabetes, including those 
of Asian ethnicity.2–5 However, most trials 
of cardiovascular risk reduction therapy in 
patients with diabetes occurred in western 
populations.
Response to these therapies can be 
affected by ethnicity. ACE inhibitors (ACEi) 
were found to be less effective in reducing 
mortality and cardiovascular events among 
black patients with hypertension and 
diabetes compared with other antihyperten-
sive agents.6–8 Several studies also reported 
higher risk of ACEi-induced cough in 
Chinese patients suggesting that there may 
be some underlying differences in response 
to these medications.9 Others reported that 
South Asians may have increased sympathetic 
activity, possibly causing differing responses 
to antihypertensive classes.10 An analysis 
in South Asian and Chinese patients with 
newly diagnosed diabetes found significant 
mortality reductions associated with statin 
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Research
strengths and limitations of this study
 ► This study addresses a substantial gap in the 
literature regarding long-term effectiveness of 
commonly used antihypertensive drug classes 
among patients with diabetes of South Asian and 
Chinese descent.
 ► The analysis is conducted on a large, population-
based data set including significant numbers of 
people of different ethnicities in Canada, allowing 
for measurement of real-world effects on mortality.
 ► Limitations include possible residual confounding 
due to unmeasured variables.
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use.10 However, similar analyses are currently lacking for 
antihypertensive agents.
The benefit of ACEi in reducing cardiovascular risk in 
diabetes was established in multiple large randomised 
control trials (RCT) of western patients, with 24% reduc-
tion in the secondary outcome of total mortality seen 
in the HOPE study.11–13 These benefits were similar to 
angiotensin receptor blockers (ARBs) based on the 
ONTARGET study subset of patients with diabetes.14 
However, the PRoFESS trial included 18% of patients 
of Chinese ethnicity and 8.4% of South Asian ethnicity, 
and found no benefit of telmisartan in reducing major 
cardiovascular events.15 Additionally, major randomised 
trials examining thiazide and thiazide-like diuretics 
(SHEP,16 ALLHAT7), calcium channel blockers (CCB) 
(ALLHAT7) and CCB-based combinations (ACCOM-
PLISH17) were conducted in predominantly western 
populations.
The burden of diabetes in South Asian and Chinese 
populations is tremendous, with these ethnic groups 
representing 62% of all adults with diabetes globally.18 
In this context, the paucity of large studies specifically 
comparing long-term effectiveness of major antihyperten-
sive drug classes in these ethnicities is concerning.19 With 
the existing, widespread use of these medications, such 
studies are unlikely to be conducted in the near future. In 
an effort to fill the information gap, we conducted a popu-
lation-based cohort study to determine whether ACEi, 
ARB, dihydropyridine CCB and diuretics are effective 
in reducing all-cause mortality in a population cohort of 
South Asian (originating from Pakistan, India or Bangla-
desh), Chinese (originating from China, Taiwan or Hong 
Kong) and other patients with newly diagnosed diabetes.
reseArch DesIgn AnD methODs
Study overview
We conducted an analysis using population-based admin-
istrative data of adults aged ≥35 years living in British 
Columbia, Canada, with newly diagnosed diabetes 
between 1 April 2006 and 31 March 2013.
Data sources
We used administrative data from British Columbia, 
Canada. We obtained deidentified linked health datasets 
through Population Data BC with approval of relevant 
data stewards and the University of British Columbia’s 
Behavioural Research Ethics Board.20 All inferences, 
opinions and conclusions drawn in this report are those 
of the authors and do not reflect the opinions or policies 
of Population Data BC.
The databases covered all British Columbians except 
those whose prescription drug coverage fell under 
federal jurisdiction (ie, military, veterans, inmates 
of federal penitentiaries and status Indians living on 
reserves, approximately 4.0% of the total population). 
All residents included in our dataset are covered under 
British Columbia’s universal, public health insurance 
programme for medical and hospital care; and all are 
eligible for coverage under British Columbia’s universal, 
public drug benefit plan, under which deductibles are set 
in relation to household income.
British Columbia has a total population of 4.6 million 
people, including approximately 210 400 South Asian 
and 373 800 Chinese people.21 22 Because the public 
health insurance programme covers virtually all health 
encounters, data from physician billing claims can be 
used to identify diagnoses. We extracted International 
Classification of Diseases (ICD-9 and ICD-10) codes 
from physician claims including both inpatient and 
outpatient encounters. Outpatient billing data include 
a single diagnosis for each encounter. Inpatient data 
include both primary (most responsible diagnosis) and 
secondary (comorbid conditions) diagnosis codes from 
hospital discharge abstracts (up to 25 codes for each 
encounter). Data on medication use were extracted 
from PharmaNet, a provincial electronic database that 
contains a record of all dispensed prescriptions from 
community pharmacies. The accuracy of this database 
against prescriptions is estimated to be greater than 
99%.23 Data on time of death were obtained from the 
vital statistics database and reporting of all deaths in the 
province is mandatory.
study population
The study population was restricted to people with a new 
diagnosis of diabetes during the study period. A new diag-
nosis of diabetes was defined as an ICD-9 or ICD-10 code 
for diabetes for at least one hospital discharge abstract 
or two physician claims within 2 years (ICD-9-CM: 250.x; 
ICD-10: E109, E119, E139, E149, E101, E111, E131, E141, 
E105, E115, E135 and E145). To ensure that these cases 
were truly new diagnoses, we set a washout period of 3 years 
(ie, no physician claims for diabetes in the preceding 3 
years). This algorithm is entirely based on administrative 
billing data, and was previously validated against physician 
diagnosis of diabetes in adults aged ≥35 years with sensi-
tivity 92% and specificity 97% in identifying diagnoses of 
diabetes in British Columbia.24–26 Index date was defined 
as the earliest contact with the healthcare system with the 
diabetes diagnosis. Patients who died within 1 month of 
diabetes diagnosis were excluded from the analysis.
categorising ethnic group
Because ethnicity is not routinely recorded in Canadian 
administrative health data, we used an algorithm devel-
oped to identify surnames of South Asian and Chinese 
origin that has been validated for use in administrative 
data research by Shah et al.27 Canadian census data show 
that 93% of South Asians and 90% of Chinese marry 
people of the same ethnic background, minimising the 
chance of misidentification due to mixed marriages.28 We 
labelled the remaining population as ‘other.’ In the prov-
ince of British Columbia, the vast majority of this group 
consists of individuals of European ancestry (>90%), with 
very few people of African ancestry (<1%).29
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sociodemographics and comorbid conditions
We estimated socioeconomic status (SES) using income 
quintile. We estimated household income based on 
a combination of household-specific and area-based 
income data.30 We also included comorbidities from the 
Charlson comorbid conditions list.31 These conditions 
were extracted from all inpatient and outpatient claims 
dating from up to 1 year prior to the index date.
cardiovascular risk reduction medications
Within each ethnicity, we classified study patients as 
either treated or untreated with each antihypertensive 
medication class: ARB, ACEi, dihydropyridine CCB and 
thiazide or thiazide-type diuretics. We considered patients 
as treated with a medication if they received at least one 
prescription within 1 year after index diagnosis, a time 
period used in other similar studies.32
Outcome measures
Patients were followed for up to 4 years for the primary 
outcome measure, time to death from any cause. Risk was 
determined for South Asian, Chinese and other patients 
treated on each medication as compared with untreated 
patients (regardless of other antihypertensive use) within 
each ethnicity as a baseline.
statistical analysis
Baseline characteristics for each ethnic group were 
summarised and compared among the groups using the 
χ2 test for categorical variables and analysis of variance for 
continuous variables. We constructed inverse probability 
of treatment weighted (IPTW) Cox proportional hazards 
models for the treatment effect on mortality.33 34 This 
method is aimed at minimising effects of confounding 
by indication.35 The weight was based on a propensity 
score of having treatment, estimated from a multivariable 
logistic regression model with receiving treatment as a 
binary outcome variable and age, gender, SES, Charlson 
comorbidities and baseline use of other medications as 
independent variables. In particular, the weight for each 
subject was computed by taking the inverse probability of 
receiving treatment that the subject received and stabi-
lised by multiplying marginal probability of the actual 
treatment received.36 Means and SD of the weights were 
assessed to verify the positivity assumption. Schoenfeld 
residuals were explored to examine the proportional 
hazards assumption. Cumulative incidence of death was 
also visualised for the weighted sample. Use of other medi-
cations (insulin, use of other antihypertensive agents and 
statins) at baseline was defined as a prescription recorded 
within 1 month before or after diagnosis. The data were 
censored at the end of the 4-year observation period or at 
death, whichever came first.
Statistical power for each drug by ethnicity was calcu-
lated using the log-rank test, specifying actual sample 
sizes, allocation ratio, treatment and event rates observed 
and HR as derived from the risk reduction observed in 
major clinical trials (online supplementary table S1). 
Estimated power was >99.9% for the other group (all 
classes) and for ARB in Chinese, >80% for ARB in South 
Asians and ACEi in Chinese patients, and <80% for the 
remaining categories.
In a sensitivity analysis to account for effects of differ-
ential drug exposure (including treatment cessation or 
switching between classes), we evaluated the association 
of level of medication adherence with mortality among 
patients who were treated with at least one of the four 
study medication classes. We constructed the IPTW Cox 
proportional hazards models to compare among the 
medication adherence levels. In particular, the adher-
ence of each medication was measured over 1 year since 
the first prescription using proportion of days covered 
(PDC), which has a high predictive validity for hospital-
isation episodes.37 The PDC is defined as [(number of 
days supply of medication in the index period)/(number 
of days in the study period)]×100. The mean PDC across 
the four classes was calculated and classified into three 
levels with PDC ≥0.80 classified as high adherence, 
0.50≤PDC<0.80 as moderate adherence and PDC <0.50 as 
low adherence.
All p values presented are two tailed, and a value of less 
than 0.05 was considered significant for all computations. 
Analyses were performed with SAS V.9.4.
results
Baseline characteristics and prescribing
There were 208 870 patients (13 755 South Asian, 22 
871 Chinese, 172 244 other) included in the analysis 
(table 1). Most patients were elderly with South Asian 
patients being younger than the other groups at time of 
diagnosis. South Asian and Chinese patients were more 
likely than other patients to be in the two lowest socio-
economic quintiles. Hypertension was present in almost 
half of patients across all ethnicities (42% South Asian, 
44% Chinese, 48% other). The prevalence of comorbid 
conditions was low in this cohort with South Asian and 
Chinese patients having generally a lower prevalence of 
conditions compared with others, including myocardial 
infarction, congestive heart failure, peripheral vascular 
disease and cerebrovascular disease.
Other patients were the most likely to be prescribed 
antihypertensive agents at baseline, with the most 
frequently prescribed classes being ACEi (23%) and 
diuretics (18%). South Asians were also likely to be 
prescribed with ACEi (16%) and diuretics (11%). 
Chinese patients had a more equal distribution among 
ACEi, ARB, CCB and diuretic prescriptions (9.1%–12%). 
By the end of 1 year since initial diabetes diagnosis, 
almost two-thirds of other patients were prescribed at 
least one antihypertensive agent, with a lower propor-
tion in South Asian and Chinese patients. The most 
frequently prescribed class of antihypertensive agent by 
this time was ACEi (26% South Asians, 18% Chinese, 
34% other), followed by diuretics (19% South Asians, 
19% Chinese, 27% other).
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Table 1 Baseline characteristics among patients with diabetes aged 35 years and older* 
Characteristics South Asian (n=13 755) Chinese (n=22 871) Other (n=172 244)
Age, mean age (years)±SD or %
  All patients 56.4±12.6 59.2±12.7 61.5±12.8
  35–49 33.2 24.7 18.8
  50–64 39.8 43.1 42.0
  65–79 23.2 25.3 29.5
  ≥80 3.87 6.8 9.7
Women (%) 45.0 48.4 45.1
Income quintile (%)
  First quintile (low) 25.6 27.4 21.2
  Second quintile 32.2 23.4 20.7
  Third quintile 20.4 20.2 20.0
  Fourth quintile 12.3 14.4 19.3
  Fifth quintile (high) 8.8 13.4 17.5
  Unknown 0.7 1.0 1.2
Comorbidities (%)
  Hypertension 42.0 44.0 47.9
  Myocardial infarction 2.2 1.0 2.6
  Congestive heart failure 3.0 2.1 5.3
  Peripheral vascular disease 0.6 1.3 2.0
  Cancer 2.8 3.8 6.3
  Cerebrovascular disease 1.8 2.0 3.2
  Chronic pulmonary disease 11.2 6.4 11.4
  Renal disease 2.2 2.3 3.1
Medications prescribed at baseline, n (%)
  ACEi 15.7 11.0 22.8
  ARB 7.2 10.0 8.7
  CCB 8.1 9.1 8.5
  Diuretic 11.3 12.4 18.3
  β-blocker 9.5 8.4 13.3
  Metformin 21.3 15.4 23.8
  Sulfonylurea 3.8 2.6 3.5
  Insulin 0.6 0.7 1.7
  Statin 24.2 20.8 26.9
Medications prescribed after 1 year of diabetes diagnosis, n (%)
  ACEi 26.1 17.8 33.5
  ARB 12.6 16.3 13.7
  CCB 12.6 13.9 12.8
  Diuretic 18.7 18.6 27.0
  Any ACEi, ARB, CCB, diuretic 55.2 47.7 64.9
*All p values comparing the three ethnic groups were less than 0.001.
 ACEi, ACE inhibitor; ARB, angiotensin receptor blocker; CCB,  calcium channel blocker.
mortality
Overall, 6.5% of patients (n=355 for South Asian, 
n=679 for Chinese, n=11 480 for other) died during 
the follow-up period (median 3 years; figure 1). Among 
other patients, ACEi (HR=0.88, 0.84–0.91; table 2), 
ARB (HR=0.69, 0.64–0.74) and diuretics (HR=0.66, 
0.63–0.69) were associated with substantial reductions 
in all-cause mortality, with minimal association observed 
with CCB (HR=1.00, 0.94–1.05). Consistent with the 
positivity assumption, the means of the stabilised weights 
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Figure 1 Cumulative incidence of death* for patients treated with ACEi, ARB, CCB and DIU according to ethnicity: (A) South 
Asian; (B) Chinese; (C) other. * Cox proportional hazards models were weighted using a propensity score model by the IPTW 
method adjusted for age, sex, SES, Charlson comorbidities and use of other medications (insulin, ACEi, ARB, beta-blockers, 
CCB, diuretics and statins) at baseline, defined as a prescription within 1 month before or after diagnosis. ACEi, ACE inhibitor; 
ARB, angiotensin receptor blocker; CCB,  calcium channel blocker; DIU, diuretics; IPTW, inverse probability of treatment 
weighted; SES, socioeconomic status.
were close to one with low SD (online supplementary 
table S2).
Similarly, among Chinese patients, ARB (HR=0.64, 
0.50–0.82) and diuretics (HR=0.77, 0.62–0.96) were 
associated with significant mortality reduction. There 
was a non-significant trend towards benefit with ACEi 
(HR=0.84, 0.69–1.03), but there was no significant associ-
ation observed with CCB.
In South Asian patients, no statistically significant 
mortality benefits were observed with ACEi (HR=0.91, 
0.71–1.17), ARB (HR=0.88, 0.63–1.25), CCB (HR=1.25, 
0.93–1.68) or diuretics (HR=0.83, 0.61–1.12).
In our sensitivity analysis that included level of drug expo-
sure in all drug classes, a moderate to high adherence to 
the four antihypertensive classes was associated with lower 
mortality among other patients compared with low adher-
ence (table 3). However, high or moderate adherence was 
not associated with reduced mortality compared with low 
adherence of antihypertensive medications among Chinese 
and South Asian patients. There was insufficient power to 
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Table 2 Association between antihypertensive medications and all-cause mortality according to ethnicity
Drug
Adjusted HR* (95% CI)
South Asian Chinese Other
HR p Value HR p Value HR p Value
ACEi 0.91 (0.71 to 1.17) 0.47 0.84 (0.69 to 1.03) 0.09 0.88 (0.84 to 0.91) <0.0001
ARB 0.88 (0.63 to 1.25) 0.48 0.64 (0.50 to 0.82) 0.0004 0.69 (0.64 to 0.74) <0.0001
CCB 1.25 (0.93 to 1.68) 0.14 0.94 (0.77 to 1.15) 0.56 1.00 (0.94 to 1.05) 0.89
Diuretic 0.83 (0.61 to 1.12) 0.22 0.77 (0.62 to 0.96) 0.02 0.66 (0.63 to 0.69) <0.0001
*Cox proportional hazards models were weighted using a propensity score model by the IPTW method adjusted for age, sex, SES, Charlson 
comorbidities and use of other medications (insulin, ACEi, ARB, beta-blockers, CCB, diuretics and statins) at baseline, defined as a 
prescription within 1 month before or after diagnosis.
ACEi, ACE inhibitor; ARB, angiotensin receptor blocker; CCB,  calcium channel blocker; IPTW, inverse probability of treatment weighted; SES, 
socioeconomic status.
Table 3 Association between medication adherence and all-cause mortality according to ethnicity





(n=13 173) p Value
Other
(n=124 594) p Value
Any ACEi, ARB, 
CCB, diuretic†
1.11 (0.71 to 1.73) 0.65 1.29 (0.83 to 2.01) 0.25 0.79 (0.72 to 0.86) <0.0001
*Cox proportional hazards models were weighted using a propensity score model by the IPTW method adjusted for age, sex, SES, Charlson 
comorbidities and use of other medications (insulin, ACEi, ARB, beta-blockers, CCB, diuretics and statins) at baseline, defined as a 
prescription within 1 month before or after diagnosis.
†HRs for patients prescribed any antihypertensive (ACEi, ARB, CCB, diuretic) with moderate or high adherence compared with low 
adherence.
ACEi, ACE inhibitor; ARB, angiotensin receptor blocker; CCB, calcium channel blocker.
analyse the effects of high versus low adherence or adher-
ence within single medication classes.
DIscussIOn
Overall, we observed substantial ethnic differences in the 
association between of cardiovascular risk reduction ther-
apies and mortality in patients with diabetes. Mortality 
reduction associated with treatment with ARB, diuretics 
and a trend towards mortality benefit with ACEi were 
observed Chinese patients. However, no significant asso-
ciations with mortality and cardiovascular risk reduction 
therapy were seen in South Asians for any drug class.
It is difficult to directly compare our findings with those 
of previous major clinical trials due to differences in study 
methodology, inability to directly compare the magnitude 
of HRs and relative risks, and due to the specification of 
all-cause mortality as a non-primary outcome in most of 
these trials. Nevertheless, the associations we observed in 
the other population are generally consistent in direc-
tion with results from major clinical trials in patients 
with diabetes.13 14 33 For ACEi, the benefit we observed 
(HR=0.88, 0.84–0.91) is consistent with findings reported 
in the HOPE study (total mortality relative risk 0.76, 0.63–
0.92) that compared ramipril to placebo in patients with 
diabetes and an additional cardiovascular risk factor.13 
The mortality reduction for ARB (HR=0.69, 0.64–0.74) is 
similar to that seen in the LIFE study (relative risk 0.61, 
0.45–0.84), comparing losartan to atenolol.38
Among Chinese patients, we observed generally similar 
mortality reductions associated with ACEi (HR=0.84, 
0.69–1.03) and ARB (HR=0.64, 0.50–0.82) use, although 
the benefit of ACEi did not reach statistical significance. 
Notably, adherence to ACEi among Chinese patients 
(52%) compared with ARB (72%) is reported to be lower 
than other patients, and this difference may have attenu-
ated the association with ACEi.23 Nevertheless, our results 
provide new evidence of these agents in a real world popu-
lation extending the findings of the ONTARGET14 study, 
that included 14% of patients of Asian ethnicity. Given 
these findings, it is particularly important to emphasise 
the increased use of these medications, particularly given 
the gaps in prescription filling observed among Chinese 
and South Asian patients, who had lower than expected 
rates of renin–angiotensin system antagonist prescription.
Diuretics were associated with reduced mortality in 
Chinese. The effects observed (Chinese HR=0.77, 0.62–
0.96) are largely consistent with those reported in the 
placebo-controlled SHEP trial16 diabetes subgroup (HR 
0.80, 0.68–0.95). The present findings are the first to our 
knowledge to evaluate thiazide and thiazide-like diuretics 
to Chinese patients with diabetes.
We did not observe substantial benefits of CCB in any 
ethnic category. This result was unexpected given the 
findings of the ALLHAT study, that showed that CCB 
were equivalent to ACEi and diuretics as first-line antihy-
pertensive agents in diabetes.7 These findings may reflect 
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the trend that CCB are decreasingly likely to be used as 
initial antihypertensive therapy compared with ACEi and 
diuretics in Canada.39 This trend is in accordance with 
guidelines promoting CCB as an add-on agent given the 
ACCOMPLISH trial findings.17 Patients in the CCB group 
may have had more severe hypertension requiring more 
than one agent, thereby causing confounding by indica-
tion. Moreover, the comparison group in our study likely 
included patients treated with other agents such as ACEi, 
ARB and diuretics, leading to an attenuation of observed 
association. It is also possible that the real-world effect size 
varies from that observed in RCTs due to rigid selection 
criteria and selection bias. Further research is required to 
clarify the benefit of CCB, especially in South Asian and 
Chinese populations.
None of the drug classes were associated with any statis-
tically significant mortality benefits among South Asians. 
A major reason for the lack of findings could have been 
a lack of power (online supplementary table S1) given 
low event rates (n=355 events, 2.6% event rate in South 
Asians; n=679 events, 3.0% in Chinese) and low prescrip-
tion filling rates in this cohort. The lower rate of mortality 
events is consistent with evidence in our population 
demonstrating a lower rate of mortality following myocar-
dial infarction, uniquely among South Asians.40 Moreover, 
the South Asian cohort had the youngest age distribution, 
and this could have led to relatively fewer mortality events 
and weaker associations particularly with diuretics, which 
may be more effective in older patients. It is conceivable 
that the association may also have been attenuated by 
additional factors such as cultural dietary practices (eg, 
salt intake41) and pharmacogenetical influences. For 
instance, ACE gene insertion/deletion polymorphisms 
affect serum levels of ACEi, although a long-term effect 
on cardiovascular outcomes has yet to be demonstrated.42 
Pharmacogenetical differences may also lead to hetero-
geneous responses to antihypertensive agents within the 
same class.43 With these considerations in mind, further 
research is required to confirm the effectiveness and 
magnitude of mortality benefit of cardiovascular risk 
reduction therapy in South Asians.
The lack of significant associations among South 
Asians may also relate to poor medication adherence 
and reduced drug exposure. Although we performed 
a sensitivity analysis using drug adherence to evaluate 
whether drug discontinuation, switching between classes, 
or decreased adherence may have affected our results, 
only in other patients was a significant mortality reduc-
tion seen in those with moderate or high adherence. No 
significant associations were observed for South Asian and 
Chinese patients. The lack of adherence effects may be 
related to inadequate power to detect smaller treatment 
related effect size in these groups. Another possibility is 
that some of these patients could have switched from one 
medication class to another, thus, attenuating the nega-
tive effects of being unexposed to the initial medication 
(eg, switching from ACEi to ARB in Chinese patients 
due to cough). South Asian and Chinese patients may 
also import antihypertensive medications from out of 
country, limiting our ability to detect treatment differ-
ences.44 In the context of these limitations, more studies 
are required to evaluate the interaction between medica-
tion adherence and antihypertensive therapies in South 
Asian and Chinese patients.
Our large population-based observational study allowed 
for measurement of real-world mortality differences, 
minimising outcome misclassification and with virtually 
no loss to follow-up in the context of Canada’s universal 
healthcare system. Although observational studies of 
this nature have been shown to generally correlate with 
RCTs,45 we recognise that our cohort had lower preva-
lence of comorbid conditions compared with the more 
high-risk populations included in clinical trials. Thus, it is 
possible that a mortality benefit for ACEi and other cardio-
vascular risk reduction therapies may indeed exist among 
the subset of high-risk South Asian (and Chinese) patients 
that was not captured in this study. Additional studies with 
a larger sample size (given the relative lack of power in the 
South Asian cohort) or with a higher-risk cohort would be 
required to evaluate this possibility, especially considering 
the Canadian recommendation that ACEi or ARB be used 
for all patients with diabetes over age 55 years—even in 
the absence of end-organ damage or hypertension.4 To 
ensure that the results are generalisable to other real-
world populations, more studies in other countries with 
different practice patterns and population compositions 
are required to improve external validity. We were also 
unable to assess for the additional benefits of combina-
tion therapies due to sample size considerations, although 
this likely would not have explained the lack of associa-
tions observed in the Asian cohorts. Further studies are 
required to assess these effects specifically in South Asian 
and Chinese populations with diabetes.46 Moreover, the 
IPTW can be used to estimate exposure effects adjusted 
for measured confounders only. However, there could 
have been residual confounding due to unmeasured vari-
ables including hypertension severity and duration, age 
of hypertension onset, treatment indication, treatment 
of previous cardiovascular comorbidities, blood pressure 
levels and haemoglobin A1C. Finally, there is a built-in 
selection bias that has been described with use of HRs.47 
Given the limitations we have described, further inves-
tigations using different methodologies are required to 
confirm the present findings.
Given the tremendous and increasing burden of 
diabetes in South Asian and Chinese patients globally, 
there is an alarming paucity of large studies evaluating the 
effectiveness of routinely used cardiovascular risk reduc-
tion therapies in these groups. ACEi, ARB and diuretics 
are likely effective among Chinese and other patients. 
Although it is likely that these drugs are effective in high-
risk patients with diabetes across all ethnicities including 
South Asians, we were unable to demonstrate this with our 
unselected, lower-risk population. Given that this study 
was not an RCT examining antihypertensive efficacy in 
these populations, these findings should be interpreted 
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with caution. More research is required to evaluate the 
effectiveness of antihypertensive agents in South Asians 
and to confirm the benefit of ACEi in Chinese patients. 
Inclusion of these groups in future clinical trials is essen-
tial to examine for differential response by ethnicity.
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